The ALDOA Metabolism Pathway as a Potential Target for Regulation of Prostate Cancer Proliferation

References

• Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Mens Health. 2018;12:1807–1823. doi:10.1177/1557988318798279
   PubMed Web of Science ®Google Scholar
• Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol. 2015;194:1537–1547. doi:10.1016/j.juro.2015.06.106
   PubMed Web of Science ®Google Scholar
• Beltran H, Prandi D, Mosquera JM, et al. Divergent clonal evolution of castration resistant neuroendocrine prostate cancer. Nat Med. 2016;22:298–305. doi:10.1038/nm.4045
   PubMed Web of Science ®Google Scholar
• Dhanalakshmi S, Singh R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene. 2005;24:1188–1202. doi:10.1038/sj.onc.1208276
   PubMed Web of Science ®Google Scholar
• Pelicano H, Martin D, Xu R, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25:4633–4646. doi:10.1038/sj.onc.1209597
   PubMed Web of Science ®Google Scholar
• Sborov DW, Haverkos BM, Harris PJ. Investigational cancer drugs targeting cell metabolism in clinical development. Expert Opin Investig Drugs. 2015;24:79–94. doi:10.1517/13543784.2015.960077
   PubMed Web of Science ®Google Scholar
• Dwarakanath B, Jain V. Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. Future Oncol. 2009;5:581–585. doi:10.2217/fon.09.44
   PubMed Web of Science ®Google Scholar
• Landau BR, Laszlo J, Stengle J, Burk D. Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. J Natl Cancer Inst. 1958;21:485–494.
   PubMed Web of Science ®Google Scholar
• Maher JC, Krishan A, Lampidis TJ. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol. 2004;53:116–122. doi:10.1007/s00280-003-0724-7
   PubMed Web of Science ®Google Scholar
• Ray U. Roy SS1: aberrant lipid metabolism in cancer cells – the role of oncolipid-activated signaling. FEBS J. 2018;285:432–443. doi:10.1111/febs.14281
   PubMed Web of Science ®Google Scholar
• Lin ZY, Chen G, Zhang YQ, et al. MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer. Mol Cancer. 2017;16:48. doi:10.1186/s12943-017-0615-x
   PubMed Web of Science ®Google Scholar
• Liang Y, Zhuo Y, Lin Z, et al. Decreased Expression of MYPT1 Contributes To Tumor Angiogenesis and Poor Patient Prognosis in Human Prostate Cancer. Curr Mol Med. 2018;18(2):100–108. doi:10.2174/1566524018666180705111342
   Google Scholar
• Ji S, Zhang B, Liu J, et al. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Cancer Lett. 2016;374:127–135. doi:10.1016/j.canlet.2016.01.054
   PubMed Web of Science ®Google Scholar
• Shi S, Ji S, Qin Y, et al. Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. Cancer Lett. 2015;360:227–233. doi:10.1016/j.canlet.2015.02.014
   PubMed Web of Science ®Google Scholar
• Long F, Cai X, Luo W, Chen L, Li K. Role of aldolase A in osteosarcoma progression and metastasis: in vitro and in vivo evidence. Oncol Rep. 2014;32:2031–2037. doi:10.3892/or.2014.3473
   PubMed Web of Science ®Google Scholar
• Du S, Guan Z, Hao L, et al. Fructose-bisphosphate aldolase A is a potential metastasis-associated marker of lung squamous cell carcinoma and promotes lung cell tumorigenesis and migration. PLoS One. 2014;9:e85804. doi:10.1371/journal.pone.0085804
   PubMed Web of Science ®Google Scholar
• Chang L, Ni J, Beretov J, et al. Identification of protein biomarkers and signaling pathways associated with prostate cancer radio resistance using label-free LC-MS/MS proteomic approach. Sci Rep. 2017;7:41834. doi:10.1038/srep41834
   PubMed Web of Science ®Google Scholar
• Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11–22. doi:10.1016/j.ccr.2010.05.026
   PubMed Web of Science ®Google Scholar
• Cai C, Chen Q-B, Han Z-D, et al. miR-195 inhibits tumor progression by targeting RPS6KB1 in Human Prostate Cancer. Clin Cancer Res. 2015;21:4922–4934. doi:10.1158/1078-0432.CCR-15-0217
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–1033. doi:10.1126/science.1160809
   PubMed Web of Science ®Google Scholar
• Patel CH, Powell JD. Warburg meets epigenetics [J]. Science. 2016;354:419–420. doi:10.1126/science.aak9776
   PubMed Web of Science ®Google Scholar
• Massie CE, Lynch A, Ramos-Montoya A, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011;30:2719–2733. doi:10.1038/emboj.2011.158
   PubMed Web of Science ®Google Scholar
• Gonzalez-Menendez P, Hevia D, Alonso-Arias R, et al. GLUT1 protects prostate cancer cells from glucose deprivation-induced oxidative stress. Redox Biol. 2018;17:112–127. doi:10.1016/j.redox.2018.03.017
   PubMed Web of Science ®Google Scholar
• Fendt SM, Bell EL, Keibler MA, et al. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res. 2013;73:4429–4438. doi:10.1158/0008-5472.CAN-13-0080
   PubMed Web of Science ®Google Scholar
• Rose IA, O’Connell EL. Studies on the interaction of aldolase with substrate analogues. J Biol Chem. 1969;244:126–134. doi:10.1016/S0021-9258(19)78201-5
   PubMed Web of Science ®Google Scholar
• Xin Li, Fengxing Jiang, Zhong Ge, et al. Fructose-Bisphosphate Aldolase A Regulates Hypoxic Adaptation in Hepatocellular Carcinoma and Involved with Tumor Malignancy. Dig Dis Sci. 2019;64(11):3215-3227. doi:10.1007/s10620-019-05642-2. Epub 2019 Apr 30
   Google Scholar
• Yamamoto T, Kudo M, Peng WX, et al. Identification of aldolase A as a potential diagnostic biomarker for colorectal cancer based on proteomic analysis using formalin-fixed paraffin-embedded tissue. Tumour Biol. 2016;37:13595–13606. doi:10.1007/s13277-016-5275-8
   PubMedGoogle Scholar
• Fu H, Gao H, Qi X, et al. Aldolase A promotes proliferation and G1/S transition via the EGFR/MAPK pathway in non-small cell lung cancer. Cancer Commun. 2018;38:18. doi:10.1186/s40880-018-0290-3
   Web of Science ®Google Scholar
• Grandjean G, de Jong PR, James B, et al. Definition of a novel feed-forward mechanism for glycolysis-HIF1α signaling in hypoxic tumors highlights Aldolase A as a therapeutic target. Cancer Res. 2016;76:4259–4269. doi:10.1158/0008-5472.CAN-16-0401
   PubMed Web of Science ®Google Scholar
• Kawai K, Uemura M, Munakata K, et al. Fructose-bisphosphate aldolase A is a key regulator of hypoxic adaptation in colorectal cancer cells and involved in treatment resistance and poor prognosis. Int J Oncol. 2017;50:525–534. doi:10.3892/ijo.2016.3814
   PubMed Web of Science ®Google Scholar
• Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem. 1994;269:23757–23763. doi:10.1016/S0021-9258(17)31580-6
   PubMed Web of Science ®Google Scholar
• Sharp FR, Bernaudin M. HIF1 and oxygen sensing in the brain. Nat Rev Neurosci. 2004;5:437–448. doi:10.1038/nrn1408
   PubMed Web of Science ®Google Scholar
• Heron PW, Abellán-Flos M, Salmon L, Sygusch J. Bisphosphonate inhibitors of mammalian glycolytic aldolase. J Med Chem. 2018;61:10558–10572. doi:10.1021/acs.jmedchem.8b01000
   PubMed Web of Science ®Google Scholar
• Uttarkar S, Dukare S, Bopp B, et al. Phosphate inhibits the activity of the transcription factor myb by blocking the interaction with the KIX domain of the coactivator p300. Mol Cancer Ther. 2015;14:1276–1285. doi:10.1158/1535-7163.MCT-14-0662
   PubMed Web of Science ®Google Scholar